Prolonged response to oral gefitinib, cyclophophamide, and topotecan in heavily pretreated relapsed stage 4 neuroblastoma: A case report

Journal of Pediatric Hematology/Oncology

Volumn 29, Issue 11, 2007, Pages 799-803

  Donfrancesco, Alberto ^a   Jenkner, Alessandro ^a   De Ioris, Maria Antonietta ^a   Ilari, Ilaria ^a   Castellano, Aurora ^a   De Laurentis, Clementina ^a   Garganese, Maria Carmen ^a   Milano, Giuseppe Maria ^a   Dominici, Carlo ^a,b  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Epidermal growth factor receptor (EGFR); Neuroblastoma; Oral chemotherapy

Indexed keywords

(3 IODOBENZYL)GUANIDINE; CARBOPLATIN; CREATININE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GEFITINIB; HOMOVANILLIC ACID; IFOSFAMIDE; IRINOTECAN; LACTATE DEHYDROGENASE; METAIODOBENZYLGUANIDINE I 123; TEMOZOLOMIDE; TOPOTECAN; UNCLASSIFIED DRUG; VANILMANDELIC ACID; VINCRISTINE;

ABDOMINAL MASS; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW BIOPSY; CANCER GROWTH; CANCER RELAPSE; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUROBLASTOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR CLASSIFICATION;

ADMINISTRATION, ORAL; ADRENAL GLAND NEOPLASMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; NEUROBLASTOMA; QUINAZOLINES; RECURRENCE; TOPOTECAN; TREATMENT OUTCOME;

EID: 35948991105     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e31815815f6     Document Type: Article

References (17)

1. Castleberry RP, Pritchard J, Ambros P, et al. The International Neuroblastoma Risk Groups (INRG): a preliminary report. Eur J Cancer. 1997;33:2113-2116.
2. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999;341:1165-1173.
3. Shintani S, Li C, Mihara M, et al. Gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor, mediates the inhibition of lymph node metastasis in oral cancer cells. Cancer Lett. 2003;201:149-155.
4. Shintani S, Li C, Mihara M, et al. Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancer. Int J Cancer. 2003;107:1030-1037.
5. Nakagawa K, Tamura T, Negoro S, et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol. 2003;14:922-930.
6. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol. 2003;21:2237-2246.
7. Daw NC, Furman WL, Stewart CF, et al. A phase I trial and pharmacokinetic study of gefitinib in pediatric patients with refractory solid tumors: A Children's Oncology Group Study. [Abstract] 2004 ASCO Annual Meeting Proceedings. Vol 22: Abstract no. 8522.
8. Furman WL, Daw NC, Crews KR, et al. A phase I study of gefitinib and irinotecan (IRN) in pediatric patients with refractory solid tumors. [Abstract] 2004 ASCO Annual Meeting Proceedings. Vol 22: Abstract no. 8521.
9. Bowers DC, Aquino VM, Leavey PJ, et al. Phase I study of oral cyclophosphamide and oral topotecan for children with recurrent or refractory solid tumors. Pediatr Blood Cancer. 2004;42:93-98.
10. Dziadziuszko R, Witta SE, Cappuzzo F, et al. Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer. Clin Cancer Res. 2006;12:3078-3084.
11. Ho R, Minturn JE, Hishiki T, et al. Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor. Cancer Res. 2005;65:9868-9875.
12. Daw NC, Santana VM, Iacono LC, et al. Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors. J Clin Oncol. 2004;22:829-837.
13. Kramer K, Kushner BH, Cheung NK. Oral topotecan for refractory and relapsed neuroblastoma: a retrospective analysis. Pediatr Hematol Oncol. 2003;25:601-605.
14. Daw NC, Furman WL, Stewart CF, et al. Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol. 2005;23:6172-6180.
15. Freeman BB, Daw NC, Geyer RG, et al. Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients. Cancer Invest. 2006; 24:310-317.
16. Cohen MH, Williams GA, Sridhara R, et al. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res. 2004;10:1212-1218.
17. Stewart CF, Leggas M, Schuetz JD, et al. Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice. Cancer Res. 2004;64:7491-7499.